H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $75.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Andrew Fein’s rating is based on the promising potential of Corbus Pharmaceuticals’ CRB-701 across various tumor types. The updated data presented at the ASCO GU 2025 conference highlighted CRB-701’s strong risk-benefit profile, particularly in comparison to other nectin-4 ADCs. The study showed no dose-limiting toxicities and a lower incidence of adverse effects such as neuropathy, which positions CRB-701 favorably against competitors like Padcev and Tivdak. Furthermore, the strong responses observed in heavily pretreated HNSCC patients indicate that CRB-701 could be effective beyond its current indications.
Fein also notes the study’s focus on safety and tolerability, which is crucial for differentiating CRB-701 from other similar therapies. The trial enrolled patients with advanced solid tumors across nine cancer types, and the results showed a manageable safety profile with most adverse events being mild or moderate. The introduction of preventative measures led to a reduction in eye-related toxicities, and skin toxicity was less frequent than with other ADCs. These findings underscore CRB-701’s competitive edge in the oncology space, supporting Fein’s Buy rating for Corbus Pharmaceuticals.
In another report released on February 16, Mizuho Securities also maintained a Buy rating on the stock with a $42.00 price target.